EUVIMEDEUVIMED entdecken
Open Access

The Use of Glucagon‐Like Peptide 1 Agonists Among Non‐Diabetics: Evidence From Medicare Part D

Minji Kim iD, Kieran Allsop, Joseph F Levy iD

Health Services Research · 2026-04 · 61 (2)

DOI: 10.1111/1475-6773.70098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Services Research, online erschienen am 11.03.2026. Verfasst von Minji Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Medicare Part D, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Off-Label Use. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the extent of off‐label glucagon‐like peptide‐1 receptor agonist (GLP‐1) prescribing among individuals without diabetes in Medicare Part D. Study Setting and Design This cross‐sectional study included Medicare Part D beneficiaries who initiated GLP‐1s. We used a difference‐in‐differences event‐study design with insulin initiators as a control group to interpret time trends in prescribing without diabetes evidence. Data Sources and Analytic Sample We identified beneficiaries initiating semaglutide or tirzepatide between 2019 and 2023 using a 20% sample of Part D event data. Nondiabetic use was defined as the absence of a diabetes diagnosis or a prescription history of diabetes medications within 1 year before or after 6 months of the first GLP‐1 fill. Principal Findings Among 126,263 new GLP‐1 users, 9.0% were prescribed without diabetes, rising to 13.8% in 2023. This practice was more common among younger, female beneficiaries with obesity. From 2021 to 2023, the share of initiators without diabetes evidence increased by 13.3 percentage points (95% CI, 12.9–13.6), beyond changes observed among insulin initiators.

Conclusions

This growth underscores the substantial budgetary implications for Medicare, particularly amid ongoing policy discussions around expanding coverage of GLP‐1s for weight management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medicare Part DHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsOff-Label UseGlucagon-Like Peptide 1Practice Patterns, Physicians'HumansUnited StatesFemaleCross-Sectional StudiesSemaglutideGlucagon-Like PeptidesTirzepatideAgedMaleAged, 80 and over

Stichwörter der Autor:innen

Medicarediabetesglucagon‐like peptide‐1 receptor agonistobesityoff‐label

Substanzen

SemaglutideGlucagon-Like PeptidesTirzepatideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Department of Economics, Johns Hopkins Krieger School of Arts and Sciences, Baltimore, Maryland, USA.

ORCID-Profile: Minji Kim, Joseph F Levy

Zitieren

APA

Kim, M., Allsop, K., & Levy, J. F. (2026). The Use of Glucagon‐Like Peptide 1 Agonists Among Non‐Diabetics: Evidence From Medicare Part D. Health Services Research, 61(2). https://doi.org/10.1111/1475-6773.70098

Vancouver

Kim M, Allsop K, Levy JF. The Use of Glucagon‐Like Peptide 1 Agonists Among Non‐Diabetics: Evidence From Medicare Part D. Health Services Research. 2026;61(2). doi:10.1111/1475-6773.70098

BibTeX
@article{Kim2026,
  author = {Kim, Minji and Allsop, Kieran and Levy, Joseph F},
  title = {The Use of Glucagon‐Like Peptide 1 Agonists Among Non‐Diabetics: Evidence From Medicare Part D},
  journal = {Health Services Research},
  year = {2026},
  volume = {61},
  number = {2},
  doi = {10.1111/1475-6773.70098}
}
Kostenlos starten →